<DOC>
	<DOCNO>NCT02502994</DOCNO>
	<brief_summary>This study design evaluate safety efficacy single injection GEN0101 patient recurrence castration resistant prostate cancer . The subject receive GEN0101 injection 4 time per two week ( 1st intratumoral injection follow subcutaneous injection ) two week observation one cycle treatment period . Each subject receive two cycle treatment period . Low dose group : 30,000m NAU per injection GEN0101 High dose group : 60,000m NAU per injection GEN0101 Each group include minimal 3 subject .</brief_summary>
	<brief_title>Phase 1 Study GEN0101 Patients With Recurrence CRPC</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Patients provide write informed consent voluntary agreement . 2 . Age 20 = &lt; = &lt; 85 year old time inform consent 3 . Have diagnosis malignant tumor confirm histology cytology . 4 . Have diagnosis recurrence castration resistant prostate cancer meet follow condition Inapplicable standard treatment , ineffective criterion Prostate Cancer Clinical Trials Working Group ( PCWG2 ) refuse standard treatment More 6 week end date standard treatment registration date standard treatment ineffective 5 . Serum PSA &lt; 100 ng/mL screen visit 6 . Expected survival period 8 week plan start date investigational product 7 . ECOG Performance Status 0 1 8 . Have injectable intraprostatic lesion confirm histologic examination 9 . The marrow function , liver function kidney function must keep follow screen visit ( 1 ) leukocyte &gt; = 3,000/mcL ( 2 ) neutrophil &gt; =1,500/mcL ( 3 ) platelet &gt; =75,000/mcL ( 4 ) hemoglobin &gt; =8.0 g/dL . ( 5 ) AST = &lt; 100 IU/L ( 6 ) ALT = &lt; 100 IU/L ( 7 ) total bilirubin = &lt; 2.5 mg/dL ( 8 ) serum creatinine = &lt; 2.5 mg/dL 1 . Have multiple brain metastasis 2 . Positive result prick test GEN0101 3 . Have serious complication uncontrolled active infection 4 . Received systemic chemotherapy , radiotherapy immunotherapy within 6 week plan registration date However hormone therapy except estramustine , enzalutamide abiraterone , bisphosphonate antiRANKL antigen antibody include systemic chemotherapy . 5 . Received another investigational medical product within 4 week inform concent 6 . Had history malignancy prostate cancer , except relapsefree metastasisfree 5 year last treatment registration 7 . Have active autoimmune disease 8 . Receiving systemic administration glucocorticosteroid restrain immunity response , except administration long period ( 6 month ) low dose ( equivalent 10 mg/day oral prednisolone ) . 9 . Had history autologous homogeneous organ tissue transplantation ( Receiving immunosuppressive medication ) 10 . PT ( % ) less 10 % low limit normal APTT 1.5 time upper limit normal local reference range screen visit 11 . Positive result hepatitis B surface antigen , HCV antibody HIV test screen visit 12 . Inappropriate enrol study judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>